PL3710457T3 - Inhibitory immunoproteasomu - Google Patents
Inhibitory immunoproteasomuInfo
- Publication number
- PL3710457T3 PL3710457T3 PL18812554.6T PL18812554T PL3710457T3 PL 3710457 T3 PL3710457 T3 PL 3710457T3 PL 18812554 T PL18812554 T PL 18812554T PL 3710457 T3 PL3710457 T3 PL 3710457T3
- Authority
- PL
- Poland
- Prior art keywords
- immunoproteasome inhibitors
- immunoproteasome
- inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/027—Organoboranes and organoborohydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762587375P | 2017-11-16 | 2017-11-16 | |
| PCT/US2018/061132 WO2019099576A1 (en) | 2017-11-16 | 2018-11-14 | Immunoproteasome inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3710457T3 true PL3710457T3 (pl) | 2023-02-20 |
Family
ID=64572584
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18812554.6T PL3710457T3 (pl) | 2017-11-16 | 2018-11-14 | Inhibitory immunoproteasomu |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US12024531B2 (pl) |
| EP (1) | EP3710457B1 (pl) |
| JP (1) | JP7333321B2 (pl) |
| KR (1) | KR102647050B1 (pl) |
| CN (1) | CN111491939B (pl) |
| AU (1) | AU2018369787B2 (pl) |
| CA (1) | CA3080958A1 (pl) |
| DK (1) | DK3710457T3 (pl) |
| ES (1) | ES2928787T3 (pl) |
| HR (1) | HRP20221292T1 (pl) |
| HU (1) | HUE060020T2 (pl) |
| LT (1) | LT3710457T (pl) |
| MX (1) | MX2020005036A (pl) |
| PL (1) | PL3710457T3 (pl) |
| PT (1) | PT3710457T (pl) |
| RS (1) | RS63666B1 (pl) |
| SI (1) | SI3710457T1 (pl) |
| WO (1) | WO2019099576A1 (pl) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE054460T2 (hu) | 2017-01-18 | 2021-09-28 | Principia Biopharma Inc | Immunproteaszóma-gátlók |
| WO2019099582A1 (en) | 2017-11-16 | 2019-05-23 | Principia Biopharma Inc. | Immunoproteasome inhibitors |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| US4963655A (en) | 1988-05-27 | 1990-10-16 | Mayo Foundation For Medical Education And Research | Boron analogs of amino acid/peptide protease inhibitors |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| IL111175A0 (en) * | 1993-10-07 | 1994-12-29 | Du Pont Merck Pharma | Electrophilic peptide analogs as inhibitors of trypsin-like serine proteases and pharmaceutical compositions containing them |
| US6083903A (en) * | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
| US7576206B2 (en) * | 2003-08-14 | 2009-08-18 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
| AU2005216970B2 (en) | 2004-02-23 | 2011-07-07 | Trustees Of Tufts College | Inhibitors of dipeptidylpeptidase IV for regulating glucose metabolism |
| SG10201605152SA (en) | 2011-12-22 | 2016-08-30 | Ares Trading Sa | Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors |
| NZ705040A (en) * | 2012-07-20 | 2017-07-28 | Cleave Biosciences Inc | Fused pyrimidines as inhibitors of p97 complex |
| US10654843B2 (en) | 2014-06-20 | 2020-05-19 | Principia Biopharma Inc. | LMP7 inhibitors |
| AU2015327345B9 (en) * | 2014-10-01 | 2020-06-18 | Merck Patent Gmbh | Boronic acid derivatives |
| HUE054460T2 (hu) * | 2017-01-18 | 2021-09-28 | Principia Biopharma Inc | Immunproteaszóma-gátlók |
| WO2019099582A1 (en) | 2017-11-16 | 2019-05-23 | Principia Biopharma Inc. | Immunoproteasome inhibitors |
-
2018
- 2018-11-14 PL PL18812554.6T patent/PL3710457T3/pl unknown
- 2018-11-14 RS RS20220964A patent/RS63666B1/sr unknown
- 2018-11-14 ES ES18812554T patent/ES2928787T3/es active Active
- 2018-11-14 MX MX2020005036A patent/MX2020005036A/es unknown
- 2018-11-14 HR HRP20221292TT patent/HRP20221292T1/hr unknown
- 2018-11-14 US US16/764,199 patent/US12024531B2/en active Active
- 2018-11-14 CN CN201880081600.1A patent/CN111491939B/zh active Active
- 2018-11-14 KR KR1020207016763A patent/KR102647050B1/ko active Active
- 2018-11-14 EP EP18812554.6A patent/EP3710457B1/en active Active
- 2018-11-14 JP JP2020526979A patent/JP7333321B2/ja active Active
- 2018-11-14 PT PT188125546T patent/PT3710457T/pt unknown
- 2018-11-14 SI SI201830791T patent/SI3710457T1/sl unknown
- 2018-11-14 DK DK18812554.6T patent/DK3710457T3/da active
- 2018-11-14 WO PCT/US2018/061132 patent/WO2019099576A1/en not_active Ceased
- 2018-11-14 CA CA3080958A patent/CA3080958A1/en active Pending
- 2018-11-14 HU HUE18812554A patent/HUE060020T2/hu unknown
- 2018-11-14 AU AU2018369787A patent/AU2018369787B2/en active Active
- 2018-11-14 LT LTEPPCT/US2018/061132T patent/LT3710457T/lt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT3710457T (pt) | 2022-10-25 |
| ES2928787T3 (es) | 2022-11-22 |
| US20230133165A1 (en) | 2023-05-04 |
| RS63666B1 (sr) | 2022-11-30 |
| US12024531B2 (en) | 2024-07-02 |
| CA3080958A1 (en) | 2019-05-23 |
| EP3710457A1 (en) | 2020-09-23 |
| CN111491939B (zh) | 2023-12-26 |
| KR20200090810A (ko) | 2020-07-29 |
| JP2021503467A (ja) | 2021-02-12 |
| SI3710457T1 (sl) | 2023-02-28 |
| DK3710457T3 (da) | 2022-10-24 |
| AU2018369787B2 (en) | 2023-04-20 |
| MX2020005036A (es) | 2020-08-17 |
| EP3710457B1 (en) | 2022-08-03 |
| AU2018369787A1 (en) | 2020-05-14 |
| LT3710457T (lt) | 2022-11-10 |
| HUE060020T2 (hu) | 2023-01-28 |
| KR102647050B1 (ko) | 2024-03-14 |
| JP7333321B2 (ja) | 2023-08-24 |
| HRP20221292T1 (hr) | 2022-12-23 |
| WO2019099576A1 (en) | 2019-05-23 |
| CN111491939A (zh) | 2020-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287113A (en) | smyd inhibitors | |
| ZA201905811B (en) | Novel inhibitors | |
| SG11202106520VA (en) | Kif18a inhibitors | |
| IL260217B (en) | lsd1 driven | |
| IL258158A (en) | New profortin inhibitors | |
| ZA201705527B (en) | TGF-ß INHIBITORS | |
| GB201713817D0 (en) | Fact checking | |
| ZA201907136B (en) | Ip6k inhibitors | |
| IL274523A (en) | Immunoproteasome inhibitors | |
| IL248895A0 (en) | Phosphatidylinositol 3-kinase inhibitors | |
| PT3571208T (pt) | Inibidores do imunoproteassoma | |
| IL265139B (en) | Dopamine-b-hydroxylase inhibitors | |
| GB201612860D0 (en) | Inhibitors | |
| IL276013A (en) | pi4kiiibeta inhibitors | |
| SG11202102379XA (en) | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | |
| GB201501004D0 (en) | Inhibitors | |
| IL274550A (en) | Dopamine-B-hydroxylase inhibitors | |
| LT3710457T (lt) | Imunoproteasomos inhibitoriai | |
| GB201520949D0 (en) | Inhibitors | |
| GB201721465D0 (en) | Inhibitors | |
| HK40033750A (en) | Immunoproteasome inhibitors | |
| GB201720189D0 (en) | Dopamine-B-hydroxylase inhibitors | |
| GB201812462D0 (en) | Inhibitors | |
| GB201804439D0 (en) | Dopamin-b-hydroxylase inhibitors | |
| GB201716867D0 (en) | MAP4K4 inhibitors |